Radiation is known to be mutagenic. The present study updates a 10-y-old study regarding pregnancy outcome and the health of offspring of women previously exposed to radioiodine ( 131 I) during thyroid carcinoma treatment, by doubling the number of pregnancies that occurred after exposure. Methods: Data on 2,673 pregnancies were obtained by interviewing female patients who were treated for thyroid carcinoma but had not received significant external radiation to the ovaries. Results: The incidence of miscarriages was 10% before any treatment for thyroid cancer; this percentage increased after surgery for thyroid cancer, both before (20%) and after (19%) 131 I treatment, with no variation according to the cumulative dose. In contrast to previously reported data, miscarriages were not significantly more frequent in women treated with radioiodine during the year before conception, not even in women who had received more than 370 MBq during that year. The incidences of stillbirths, preterm births, low birth weight, congenital malformations, and death during the first year of life were not significantly different before and after 131 I therapy. The incidences of thyroid and nonthyroid cancers were similar in children born either before or after the mother's exposure to radioiodine. Conclusion: There is no evidence that exposure to radioiodine affects the outcomes of subsequent pregnancies and offspring. The question as to whether the incidences of malformations and thyroid and nonthyroid cancers are related to gonadal irradiation remains to be established. The doubling dose is still being heatedly debated, and the value of 1 Gy as the doubling dose in humans should be reevaluated.Key Words: differentiated thyroid carcinoma; radioiodine therapy; pregnancy outcome; radiation dose; ovaries Radi oiodine ( 131 I) is widely used in the treatment of thyroid cancer (1,2), and the high 131 I activities administered may deliver significant radiation doses to the ovaries.Treatment with radioiodine usually consists of administering 3,700 MBq (100 mCi), and the radiation dose to the ovaries has been estimated to be 140 mGy for 3,700 MBq (3). However, very few studies have reported on outcomes, such as miscarriages, congenital abnormalities, and malignancies, in the offspring of young women treated for this cancer (4,5).In 1996, we reported the largest study on pregnancies (n 5 2,113) occurring after 1970, 258 of which occurred after exposure to radioiodine (6). The only adverse effect observed was an increased incidence of miscarriages in women exposed to therapeutic radioiodine during the year preceding conception. On the basis of that study, we recommended postponing conception for 1 y after the therapeutic administration of radioiodine and until the thyroid hormone status was verified. However, in that same study, only 96 pregnancies occurred after exposure to activities exceeding 3,700 MBq. We present here an update of that study, by doubling the number of pregnancies that occurred after 131 I therapy.
MATERIALS AND METHODS
Pa...